-
Mashup Score: 0
The phase 3 MOTION study met its primary end point of objective response rate at week 25, as well as key secondary end points, when patients with tenosynovial giant cell tumor were given vimseltinib.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Based on results from a phase 1b study of pimicotinib showing the therapys efficacy in patients with tenosynovial giant cell tumor, the agent has gained breakthrough therapy designation from the FDA.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Little information is available regarding the therapeutic efficacy of immune checkpoint inhibitors and the prediction of DNA damage-repair (DDR) genes in mixed testicular germ-cell tumors (TGCTs). Here we report a pretreated patient with metastatic mixed TGCT harboring variations of three important DDR genes – BRCA2, MSH6 and PMS2 – identified by next-generation sequencing using plasma-based…
Source: ImmunotherapyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Association Study between Polymorphisms in DNA Methylation–Related Genes and Testicular Germ Cell Tumor Risk - 2 year(s) ago
AbstractBackground:. Testicular germ cell tumors (TGCT), histologically classified as seminomas and nonseminomas, are believed to arise from primordial gonocytes, with the maturation process blocked when they are subjected to DNA methylation reprogramming. SNPs in DNA methylation machinery and folate-dependent one-carbon metabolism genes have been postulated to influence the proper establishment…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
24% of TGCT patients in the study required 5 or more visits to different specialists before receiving a proper diagnosis.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
AMB-05X has been granted fast track designation for the treatment of patients with tenosynovial giant cell tumor of the knee by the FDA.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
The FDA has granted fast track designation to AMB-05X for the treatment of patients with tenosynovial giant cell tumors.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
24% of TGCT patients in the study required 5 or more visits to different specialists before receiving a proper diagnosis.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
24% of TGCT patients in the study required 5 or more visits to different specialists before receiving a proper diagnosis.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
24% of TGCT patients in the study required 5 or more visits to different specialists before receiving a proper diagnosis.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
The primary end point of ORR at week 25 was met in the pivotal, phase 3 MOTION study investigating vimseltinib in patients with tenosynovial giant cell tumor not amenable to surgery. #TGCT | @hgelderblom @LUMC_Leiden https://t.co/9beDlZbdcH